LGNYZ Projected Dividend Yield
General Contingent Value Rt/Ligand Pharmaceuticals Inc ( OTCBB : LGNYZ )Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. Co. does this by providing financing, licensing its technologies or both. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled several U.S. Food and Drug Administration (FDA)-approved products, including Gilead's Veklury, Amgen's Kyprolis, Baxter International's Nexterone, Melinta Therapeutics' Baxdela and Sage Therapeutics' Zulresso. 24 YEAR PERFORMANCE RESULTS |
|
LGNYZ Dividend History Detail LGNYZ Dividend News LGNYZ Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
2026 |
Dec 19, 2025 |
Dec 29, 2025 |
Dec 29, 2025 |
Jan 02, 2026 |
0.0008 |
2026 Total: |
0.0008 |
||||
2025 |
Jun 26, 2025 |
N/A |
Jun 26, 2025 |
Jul 01, 2025 |
0.0475 |
2025 Total: |
0.0475 |


